# Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

> **NCT05249114** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Providence Health & Services** · enrollment: 6 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** Cabozantinib
- **DRUG:** Lu-177

## Key facts

- **NCT ID:** NCT05249114
- **Lead sponsor:** Providence Health & Services
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-28
- **Primary completion:** 2027-12
- **Final completion:** 2029-12
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05249114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05249114, "Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05249114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*